<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
                      "http://www.w3.org/TR/html4/strict.dtd">
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta name="generator" content="hypermail 2.1.5, see http://www.hypermail.org/">
<title>Extropians: RE: Performance enhancement with selegiline</title>
<meta name="Author" content="Rafal Smigrodzki (rms2g@virginia.edu)">
<meta name="Subject" content="RE: Performance enhancement with selegiline">
<meta name="Date" content="2003-02-07">
<style type="text/css">
body {color: black; background: #ffffff}
h1.center {text-align: center}
div.center {text-align: center}
</style>
</head>
<body>
<h1>RE: Performance enhancement with selegiline</h1>
<!-- received="Fri Feb  7 10:47:10 2003" -->
<!-- isoreceived="20030207174710" -->
<!-- sent="Fri, 7 Feb 2003 12:56:04 -0500" -->
<!-- isosent="20030207175604" -->
<!-- name="Rafal Smigrodzki" -->
<!-- email="rms2g@virginia.edu" -->
<!-- subject="RE: Performance enhancement with selegiline" -->
<!-- id="BMEDJIBJGLNDOOANGIDLGEKOCJAA.rms2g@virginia.edu" -->
<!-- charset="iso-8859-1" -->
<!-- inreplyto="007301c2ce82$3b138300$865f87d8@pavilion" -->
<!-- expires="-1" -->
<p>
<strong>From:</strong> Rafal Smigrodzki (<a href="mailto:rms2g@virginia.edu?Subject=RE:%20Performance%20enhancement%20with%20selegiline"><em>rms2g@virginia.edu</em></a>)<br>
<strong>Date:</strong> Fri Feb 07 2003 - 10:56:04 MST
</p>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2272.html">Alex Ramonsky: "Re: Where the I is"</a>
<ul>
<li><strong>Previous message:</strong> <a href="2270.html">Rafal Smigrodzki: "RE: Performance enhancement with selegiline"</a>
<li><strong>In reply to:</strong> <a href="2249.html">gts: "Re: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2304.html">ct: "RE: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2304.html">ct: "RE: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2308.html">gts: "Re: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2310.html">Alex Ramonsky: "Re: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2271">[ date ]</a>
<a href="index.html#2271">[ thread ]</a>
<a href="subject.html#2271">[ subject ]</a>
<a href="author.html#2271">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<hr>
<!-- body="start" -->
<p>
gts wrote:
<br>
<p><em>&gt;
</em><br>
<em>&gt; Many, many dozens of published studies state, suggest, or offer
</em><br>
<em>&gt; evidence of the neuroprotective value of selegiline in PD.
</em><br>
<p>### Show me any class A studies to this effect.
<br>
<p>Listing dozens of animal studies is perfectly irrelevant - in clinical
<br>
medicine animal studies are not even class C evidence, they are not evidence
<br>
at all.
<br>
<p>&quot;Neuroprotection in PD&quot; means that the rate of neuron loss is reduced
<br>
compared to a control group. There must be a clinical effect, or else the
<br>
neuroprotection (if detected post mortem) is useless.
<br>
<p>There must be either, maintenance of UPDRS improvement after washout of the
<br>
drug, or delay to untreatable disability, or delay of death. Neither
<br>
occurred in DATATOP.
<br>
<p>The class A study, DATATOP, shows no evidence of clinically significant
<br>
neuroprotection. Period. End of discussion.
<br>
<p>------------------
<br>
<em>&gt;&gt;&gt; As background: there was once a hypothesis that levodopa
</em><br>
<em>&gt;&gt;&gt; accelerates the attrition of dopaminergic neurons, and that
</em><br>
<em>&gt;&gt;&gt; levodopa-sparing therapy would delay the onset of dyskinesias which
</em><br>
<em>&gt;&gt;&gt; usually develop after about 5-7 years on levodopa, and perhaps
</em><br>
<em>&gt;&gt;&gt; prolong survival. A nice hypothesis, but not true -substituting
</em><br>
<em>&gt;&gt;&gt; dopa-agonists or selegiline for levodopa in initial treatment does
</em><br>
<em>&gt;&gt;&gt; not delay the onset of dyskinesia. ...
</em><br>
<em>&gt;
</em><br>
<em>&gt; I think are mistaken here to include selegiline in the same class of
</em><br>
<em>&gt; drugs as levodopa. Levodopa is merely a simple dopamine agonist --
</em><br>
<em>&gt; actually it's not even that -- it's merely an ordinary amino acid and
</em><br>
<em>&gt; a precursor to dopamine. Selegiline's actions are far more complex
</em><br>
<em>&gt; and less well understood.
</em><br>
<p>### I think you are mistaken to say I included selegiline in the same class
<br>
of drugs as levodopa.
<br>
<p>------------------------
<br>
<p><p><em>&gt;
</em><br>
<em>&gt; If you were really on top of this subject, Rafal, then I believe you
</em><br>
<em>&gt; and I would not be arguing whether selegiline is neuroprotective.
</em><br>
<p>### OK, I am just too incompetent to discuss PD with you.
<br>
<p>All my years of training as a neurologist, my movement disorders fellowship,
<br>
and you simply crush me with the abstracts of a few little rat studies.
<br>
<p>On the other hand, if you were a neurologist and a scientist you would not
<br>
waste anybody's time with fuzzy tissue-culture experiments and try to treat
<br>
them as adequate arguments against double-blind placebo controlled studies.
<br>
<p>-----------------------
<br>
<p>&nbsp;Other studies show
<br>
<em>&gt; that selegiline increases lifespan in &lt;snip&gt; human PD
</em><br>
<em>&gt; patients.
</em><br>
<em>&gt;
</em><br>
### Quote them and show they are more reliable and trustworthy than DATATOP.
<br>
<p>Rafal
<br>
<!-- body="end" -->
<hr>
<ul>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2272.html">Alex Ramonsky: "Re: Where the I is"</a>
<li><strong>Previous message:</strong> <a href="2270.html">Rafal Smigrodzki: "RE: Performance enhancement with selegiline"</a>
<li><strong>In reply to:</strong> <a href="2249.html">gts: "Re: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2304.html">ct: "RE: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2304.html">ct: "RE: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2308.html">gts: "Re: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2310.html">Alex Ramonsky: "Re: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2271">[ date ]</a>
<a href="index.html#2271">[ thread ]</a>
<a href="subject.html#2271">[ subject ]</a>
<a href="author.html#2271">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<!-- trailer="footer" -->
<hr>
<p><small><em>
This archive was generated by <a href="http://www.hypermail.org/">hypermail 2.1.5</a> 
: Fri Feb 07 2003 - 10:49:27 MST
</em></small></p>
</body>
</html>
